Atlas FDA

Predicate Research Report · generated 2026-08-22 · Print / save as PDF · Save to account

Thrombolex, Inc. — Predicate Candidate Screening

6 FDA 510(k) clearances under this manufacturer; the 50 most recent screened below.

62 daysmedian FDA review time
276 days90th percentile
6clearances measured
K-numberDeviceApplicantDecidedReview daysRecalls (K-match)
K231653BASHIR™ .035 Endovascular Catheter, BASHIR™ S-B .035 EndovasThrombolex, Inc.2023-07-03270
K222095BASHIR Endovascular Catheter Ref. No. 7201, BASHIR S-B EndovThrombolex, Inc.2023-04-202760
K211061BASHIR Endovascular Catheter (Ref. 7201), BASHIR Plus 10 EndThrombolex, Inc.2021-06-10620
K193071Bashir Plus Endovascular CatheterThrombolex, Inc.2019-12-17430
K192598Bashir S-B Endovascular Catheter, Ref. No. 7101Thrombolex, Inc.2019-10-18280
K183290Bashir Endovascular Catheter Model 7201, Bashir N-X EndovascThrombolex, Inc.2019-02-25910

Methodology

Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.

Prepared with Atlas

Predicate research, review-time statistics and recall monitoring for 510(k) teams — atlasbyauro.com/fda